ThermoGenesis Holdings, Inc. (THMO)
| Market Cap | 15.47M |
| Revenue (ttm) | 9.52M |
| Net Income (ttm) | -17.55M |
| Shares Out | 6.71M |
| EPS (ttm) | -3.86 |
| PE Ratio | n/a |
| Forward PE | 2.28 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $2.46 |
| Previous Close | $2.37 |
| Change ($) | 0.09 |
| Change (%) | 3.80% |
| Day's Open | 2.40 |
| Day's Range | 2.16 - 2.48 |
| Day's Volume | 513,293 |
| 52-Week Range | 1.63 - 14.18 |
RANCHO CORDOVA, Calif., Feb. 17, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. ("ThermoGenesis" or the "Company") (Nasdaq: THMO), a market leader in automated cell processing tools and ser...
ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q3 2020 Results - Earnings Call Transcript
RANCHO CORDOVA, Calif., Nov. 12, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy ...
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...
ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q2 2020 Results - Earnings Call Transcript
RANCHO CORDOVA, Calif., Aug. 14, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc.
RANCHO CORDOVA, Calif., Aug. 11, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings: Many Short-Term Catalysts In Low-Float Stock
RANCHO CORDOVA, Calif., June 23, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy ...
RANCHO CORDOVA, Calif., June 8, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy f...
RANCHO CORDOVA, Calif., May 28, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy f...
ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q1 2020 Results - Earnings Call Transcript
RANCHO CORDOVA, Calif., May 14, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy f...
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
As of late, it has definitely been a great time to be an investor in ThermoGenesis Holdings, Inc. (THMO).
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Thermogenesis Holdings Inc (NASDAQ: THMO) shares are trading higher on Thursday.
ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q4 2019 Results - Earnings Call Transcript
The Reincarnation Of ThermoGenesis With A Better Mousetrap For CAR-T Manufacturing
About THMO
ThermoGenesis Holdings develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company operates through two segments, Device and Clinical Development. It manufactures a... [Read more...]
| Industry Medical Devices | Founded 1986 |
| CEO Xiaochun Xu | Employees 50 |
| Stock Exchange NASDAQ | Ticker Symbol THMO |
Financial Performance
In 2019, THMO's revenue was $13.05 million, an increase of 34.89% compared to the previous year's $9.67 million. Losses were -$9.50 million, -76.09% less than in 2018.
Analyst Forecasts
According to one analyst, the rating for THMO stock is "Buy" and the 12-month stock price forecast is 8.50.